Previous Article | Next Article 
Journal of Clinical Microbiology, April 2009, p. 1136-1142, Vol. 47, No. 4
0095-1137/09/$08.00+0 doi:10.1128/JCM.01592-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Evaluation of Phenotypic Tests for Detection of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Strains in China
Ting-ting Qu,1
Jun-li Zhang,1
Jie Wang,2
Jing Tao,1
Yun-song Yu,1*
Ya-gang Chen,1
Jian-ying Zhou,2 and
Lan-juan Li1
State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China,1
Respiratory Department, First Affiliated Hospital, Medical School, Zhejiang University, Hangzhou, Zhejiang, China2
Received 16 August 2008/
Returned for modification 12 November 2008/
Accepted 2 February 2009

ABSTRACT
A total of 264 nonduplicate strains of imipenem (IPM)-nonsusceptible
Pseudomonas aeruginosa were isolated from hospitals in 16 different
regions throughout China. These 264 IPM-nonsusceptible clinical
isolates of
P. aeruginosa were examined by PCR, a metallo-β-lactamase
(MBL) Etest, a double-disk synergy test (DDST), and a test using
combined IPM disks supplemented with various amounts of EDTA.
A total of 24 strains positive for MBLs were confirmed by PCR
and DNA sequence analysis: 10 strains positive for the
blaVIM-2 gene, 13 strains positive for the
blaIMP-9 gene, and 1 strain
positive for the
blaIMP-1 gene. Real-time reverse transcriptase
PCR (RT-PCR) was used to verify whether the isolates harboring
MBL genes produced the enzyme and was considered the standard
for evaluation of the methodology in this study. Of these 24
MBL-positive stains, 21 were confirmed as MBL-producing strains
by real time RT-PCR for MBL expression and the other 3 had no
expression of MBLs. The sensitivities, specificities, and positive
and negative predictive values for the MBL Etest, the DDST,
and the combined disk (CD) assay were evaluated. The best method
for screening for MBL production in
P. aeruginosa strains from
China was the CD assay (IMP-EDTA) using 750 µg of EDTA/disk
with a breakpoint of

6 mm. In the CD assay (IPM-EDTA) with 290
µg and 750 µg EDTA, the zone diameter increases
for VIM-2-producing
P. aeruginosa isolates were greater than
those for IMP-9-producing
P. aeruginosa isolates (
P = 0.00).

INTRODUCTION
The worldwide spread of acquired metallo-β-lactamases (MBLs)
in clinically important pathogens, such as
Pseudomonas spp.,
Acinetobacter spp., and members of the
Enterobacteriaceae family,
has become a great concern (
9,
12). Increased mortality rates
have been documented for patients infected with MBL-producing
Pseudomonas aeruginosa, and these rates are especially due to
inadequate empirical therapy (
27). Most of the MBL-encoding
genes reside on class 1 integrons and plasmids that usually
confer high mobility to these genetic elements (
8,
17,
22,
24,
26). Therefore, early detection of MBL-producing organisms is
of crucial importance for prevention of their inter- and intrahospital
dissemination, not only in institutions with high prevalences
of such isolates but also in those in which phenotypes of resistance
have never been detected. Various criteria for screening for
MBL production in
P. aeruginosa have been suggested (
15). Currently,
the most widely accepted standardized MBL functional screen
is the MBL Etest (AB BioDisk, Solna, Sweden). However, due to
the high cost and unavailability of Etest strips, many clinical
microbiology laboratories use alternative screening methods,
such as the double-disk synergy test (DDST) and the combined
disk (CD) assay. Although the DDST and the CD assay are simple
to perform and cheaper than the MBL Etest, they have shown discordant
results, depending on the employed methodology, β-lactam
substrates, MBL inhibitors (IMBL), and bacterial genus tested
(
7,
11,
14,
15). Standardization of a phenotypic method for
screening for MBL-producing isolates is of crucial importance.
It is desirable that the selection of the appropriate MBL test
be based upon studies providing sensitivity (SN) and specificity
(SP) results for that specific pathogen.
Although the prevalence of MBL-producing P. aeruginosa was lower in China than elsewhere, the MBL-encoding genes are usually carried by mobile genetic structures with great ability to spread (26). The aim of this study was to evaluate the accuracy of phenotypic tests for screening for MBL-producing isolates among P. aeruginosa isolates in China.

MATERIALS AND METHODS
Bacterial isolates.
From July 2006 to July 2007, a total of 264 nonduplicate imipenem
(IPM)-nonsusceptible
P. aeruginosa isolates were collected from
hospitals in 16 different regions throughout China. All of these
isolates were isolated from different patients and were identified
with the API 20NE system (bioMérieux, Marcy l'Etoile,
France).
P. aeruginosa ATCC 27853 was used as an MBL-negative
control. Four
P. aeruginosa strains producing VIM-2 and two
P. aeruginosa strains producing IMP-1 in our laboratory were
used as MBL-positive controls (
26).
Susceptibility testing.
The MICs of IPM and meropenem (MEM) were determined by agar dilution. The results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI; 2007). P. aeruginosa ATCC 27853 was used as a control strain for susceptibility testing.
Phenotypic detection of MBL.
All 264 IPM-nonsusceptible clinical isolates of P. aeruginosa and the 6 MBL-positive control strains were tested by the three tests for phenotypic detection of MBL (the Etest, the DDST, and the CD test).
MBL Etests.
We performed MBL Etests (IPM-EDTA; AB Biodisk), following the manufacturer's recommendations.
DDST.
The phenotypic tests were performed, following the CLSI recommendations for the disk diffusion method. A 0.5 McFarland bacterial suspension was inoculated on a Mueller-Hinton (MH) agar plate (Oxoid, Basingstoke, England). IPM (10 µg) and ceftazidime (CAZ; 30 µg) disks were aligned around blank filter disks containing 3 µl mercaptopropionic acid (MPA; Sigma) or 10 µl 0.1 M EDTA (Sigma, Germany), added directly on the disk already placed on the MH agar plate. The following distances between the inhibitor and the substrates were tested: 1.5, 2.0, and 2.5 cm (from center to center). Enhancement of the zone of inhibition in the area between the antimicrobial agents and the inhibitor disk was considered to indicate positivity for MBL (Fig. 1).
CD.
For the CD assay, IPM disks (10 µg) were initially placed
on the MH plates inoculated with the 0.5 McFarland bacterial
suspension. The IMBL solutions (EDTA) added to the disks were
290 µg, 750 µg, and 930 µg, respectively (
2,
6,
16,
25). After a 24-h incubation period at 35°C, the
increase of the inhibition zone obtained with the CD was compared
to that obtained with the antimicrobial disk alone. The positive
criteria for classifying an isolate as an MBL producer are described
below.
MBL gene PCR amplification and sequencing.
PCR assays were performed to amplify the sequences of the blaIMP, blaVIM, blaGIM, blaSPM, and blaSIM genes, as previously described (3, 10, 18, 19). The PCR products were purified by using a 3S spin PCR product purification kit (Shenergy Biocolor, China) and then sequenced.
Analysis of MBL gene expression by real-time RT-PCR.
For gene expression studies, total RNA was prepared using the TRIzol Max method (Invitrogen, Carlsbad, CA). Real-time reverse transcriptase PCR (RT-PCR) was performed using 250 ng of DNase-treated RNA, a PrimeScript RT reagent Kit (Takara, Japan), and specific internal IMP and VIM primer pairs. The primers for PCR amplification of cDNA were designed using the Primer3 program (available at http://frodo.wi.mit.edu/) and are shown in Table 1. Expression of the endogenous control gene rpsL was used to normalize data (5). Primer efficiency studies were carried out before the RNA expression levels of the isolates were compared. The primers showed 100% SN and 100% SP for detecting VIM and IMP MBLs. All of the MBL genes were sequenced. Searches for similarities between the sequences and those in sequence databases were performed with the BLAST program at the National Center for Biotechnology Information server (http://www.ncbi.nlm.nih.gov/). All the genes were 100% identical. The efficiencies for amplification were 80% to 100%. Real-time RT-PCRs were carried out using an Opticon 2 real-time PCR detector, and the results were analyzed with the Opticon 2 real-time PCR detection software program. Relative quantification was determined by the 2–
CT method, where CT is the cycle threshold (13). The P. aeruginosa strain producing VIM-2, H22 (one of the MBL-positive control strains), was used as the reference strain.
Statistical analysis.
SN, SP, positive predictive value (PPV), and negative predictive
value (NPV) were calculated for the MBL Etest (IPM-EDTA), the
DDST for each β-lactam-IMBL combination, and the CD assay
for different increases of the inhibition zone. Since not all
of the strains harboring MBL genes confirmed by PCR produce
MBLs, real-time RT-PCR was used to detect the expression levels
of MBL genes. Real-time RT-PCR results for MBL expression were
used to verify whether the isolates harboring MBL genes produced
the enzyme and were considered the standard for evaluation of
the methodology.
The results from the CD phenotypic method were characterized by receiver operating characteristic (ROC) curves to determine the best cutoff values for indicating MBL production. For various amounts of EDTA, SN and SP were calculated successively according to the variation of inhibition zones of MBL-producing and -nonproducing isolates. CD results stratified into groups according to which MBL type was produced were also analyzed by ROC curve analysis and the Student t test.

RESULTS
Prevalence of MBL-producing isolates among IPM-nonsusceptible P. aeruginosa isolates.
Among the 264 IPM-nonsusceptible
P. aeruginosa isolates collected
throughout China, 24 were confirmed to be positive for MBLs
by PCR and DNA sequence analysis (10 strains positive for the
blaVIM-2 gene, 13 strains positive for the
blaIMP-9 gene, and
1 strain positive for the
blaIMP-1 gene), and no other MBLs
were detected. These 24 strains were divided into nine pulsotypes
by pulsed-field gel electrophoresis (PFGE): six pulsotypes positive
for VIM-2, two pulsotypes positive for IMP-9, and one pulsotype
positive for IMP-1 (see Table
4). The results for PFGE were
interpreted according to the criteria of Tenover et al. (
20).
View this table:
[in this window]
[in a new window]
|
TABLE 4. MBL gene expression levels, MBL Etest results, CD results, and IPM and MEM MICs for the 24 MBL-positive strains in this study
|
Expression of MBL genes by real-time RT-PCR.
Among these 24 MBL-positive strains, 3 had no expression of
MBL: zy8 (IMP-1), tj22 (VIM-2), and ss37 (VIM-2). The expression
levels of MBL genes among the 24 MBL-positive strains are shown
in Table
4. The expression levels of MBL genes were also confirmed
by isoelectric focusing according to established methods with
the PhastSystem (Pharmacia, Uppsala, Sweden) (
23).
Phenotypic MBL detection by the DDST.
Table 2 shows the SN, SP, PPV, and NPV results for the DDST. Among the 264 IPM-nonsusceptible P. aeruginosa isolates, EDTA provided the best results with CAZ used as a substrate. The SN, SP, PPV, and NPV results at 1.5 cm were 90.5, 97.5, 76.0, and 99.2%, respectively. Other DDST results with better SN and SP were obtained with either CAZ-MPA at 2.5 cm (95.2% and 91.4%) or IPM-MPA at 1.5 cm (85.7% and 93.8%). However, the PPVs for CAZ-MPA and IPM-MPA were lower (48.8% and 54.6%), overestimating the number of MBL-positive isolates.
Phenotypic MBL detection by the CD assay.
In the CD assay, the zone diameters were found to be similar
and reproducible when the procedure was repeated. All the CD
(IPM-EDTA) test results were applied in ROC curve analysis to
establish the best breakpoint (increase in mm) for MBL detection
(Fig.
2). The best breakpoint for the CD assay (IPM-EDTA) with
290 µg EDTA for indicating MBL production was 2 to 3 mm,
which was difficult to discriminate (Fig.
2). The best breakpoint
for the CD assay (IPM-EDTA) with 750 µg and 930 µg
EDTA for indicating MBL producers was 5 to 7 mm (Fig.
2). So,
the breakpoints of 4 mm, 6 mm, and 7 mm were selected to evaluate
the values for the CD assays. Table
3 shows the CD results for
various breakpoints. The best results for indicating MBL producers
were obtained using 750 µg of EDTA/disk with a breakpoint
of

6 mm. The SN, SP, PPV, and NPV for the CD assay (IMP-EDTA)
with these criteria were all 100% (Table
3). The results for
these criteria were better than those for the DDST and even
the MBL Etest (Table
3). However, among several MBL-negative
isolates, the zone diameters of IPM increased greatly (to 16
and 19 mm) when 930 µg EDTA was added to the CD assay.
So, the EDTA amounts of 290 µg and 930 µg were not
adapted to separate MBL producers.
In addition, it is interesting that distinct results for the
zone diameter increase were observed between the IMP-9- and
VIM-2-producing
P. aeruginosa isolates. The best breakpoints
in the CD assay with 290 µg and 750 µg EDTA added
to separate these two MBL types (VIM-2 and IMP-9) were 6.25
and 8.5 mm, respectively, by ROC curve analysis (Fig.
3). The
zone diameter increases for VIM-2-type producers (11.75 ±
3.41 mm and 13.69 ± 4.19 mm) were greater than those
for IMP-9-type producers (4.85 ± 1.20 mm and 7.27 ±
0.73 mm) in the CD assay with 290 µg and 750 µg
EDTA. The difference in diameter increase between the IMP-9-producing
isolate group and the VIM-2-producing isolate group was substantial
(
P = 0.00).
MBL Etest.
In our study, the overall performance of the MBL Etest (IPM-EDTA)
revealed SN, SP, PPV, and NPV results of 85.7%, 100%, 100%,
and 98.8%, respectively (Table
3). No false-positive results
were found by the MBL Etest (IPM-EDTA) among the 240 isolates
of
P. aeruginosa negative for MBL genes. There were six MBL-positive
strains with negative results for the MBL Etest, with three
of these strains (Tj22, Ss37, and Zy8) having no expression
of MBL genes (the VIM-2 and IMP-1 genes) and three (Ga8, Ga9,
and Ga16) negative for the IMP-9 gene (Table
4).

DISCUSSION
The prevalence of MBL-positive strains among IPM-nonsusceptible
P. aeruginosa isolates from hospitals in China was estimated
at 9.1% (24/264), lower than those for some developed countries,
such as Japan. The MICs of IPM and MEM have no correlation with
the expression levels of MBL genes. Also, most of the non-MBL
producers in our study had high-level resistance to IPM and
MEM. Decreased permeability and increased efflux are the most
prevalent carbapenem resistance mechanisms in Chinese clinical
isolates of
P. aeruginosa (data not shown). PFGE of SpeI-digested
genomic DNA showed that organisms from different regions are
grouped into various PFGE types. These findings suggest that
transmission of the
blaVIM-2 and
blaIMP-9 genes among clinical
strains with different genetic backgrounds may be associated
with mobile genetic elements, such as transposons and transferable
plasmids, instead of a clonal expansion of an MBL-carrying strain
throughout China. Since most of the MBL-encoding genes reside
on class 1 integrons and/or plasmids that usually confer high
mobility to these genetic elements, early detection of MBL-producing
isolates is important for avoiding dissemination of such strains.
Various criteria for screening for MBL production in P. aeruginosa have been suggested. However, there are no standard guidelines provided by the CLSI for detection of these enzymes in various bacterial species. It is desirable that the selection of the appropriate MBL test be based upon studies providing SN and SP results for that specific pathogen. The MBL Etest has been evaluated in several studies and found to be a sensitive method for detection of MBL production in P. aeruginosa (21). However, in this study, several MBL-producing strains could not be detected by the MBL Etest (IMP-EDTA). Also, the MBL Etest, PCR, and even real-time RT-PCR were expensive and not adaptable for extensive use in clinical microbiology laboratories. The DDST and the CD assay have been reported to be simple, inexpensive phenotypic resources for detection of MBL that could be easily incorporated into the routines of clinical laboratories.
In the CD assay, the best separation between MBL-positive and -negative isolates was obtained using 750 µg of EDTA/disk with a breakpoint of
6 mm. It is known that EDTA may increase bacterial cell wall permeability and that zinc (chelated by EDTA) accelerates IPM decomposition and decreases OprD expression of P. aeruginosa. (4). These nonspecific effects might cause false-positive MBL results in the CD assay with 930 µg EDTA added but not in that with 290 µg and 750 µg EDTA added. Interestingly, the zone diameter increases for VIM-2-producing P. aeruginosa isolates were found to be greater than those for IMP-9-producing P. aeruginosa isolates in the CD assay (IPM-EDTA) with 290 µg and 750 µg EDTA. The phenotypic difference may be associated with the difference in inhibition ability of EDTA between the VIM- and IMP-type MBLs. This presumption needs to be confirmed by more MBL producers. However, no isolates containing other MBLs are available in this study. It is a conceded possibility that these results may not apply in general to other MBLs not evaluated in these experiments.
The SN, SP, PPV, and NPV for the CD assay (IPM-EDTA) using 750 µg of EDTA/disk with a breakpoint of
6 mm were better than those for the DDSTs and even the MBL Etest (IPM-EDTA). Additionally, interpretation of the CD assay results is more objective than that of the DDST results because the DDST depends upon the technician's expertise in discriminating true synergism from intersection of inhibition zones. Our results were in accordance with those obtained by Berges et al. but not with those obtained by Picão et al. (2, 15). Most previous studies evaluating MBL phenotypic detection were performed under distinct experimental conditions, jeopardizing comparison of their results (6, 11, 14). The sizes of inhibition zones produced by β-lactam-IMBL combinations may differ according to the way that IMBL is incorporated into the β-lactam disks (1). In the current study, we added the IMBL solutions directly on β-lactam disks already placed on the agar plate, as described by Picão et al., whereas some authors first prepare and freeze IMBL-β-lactam disks; thus, the results of our CD assay may be comparable to those of studies using the same methodology (1, 15, 25). It has been suggested that the selection of the optimal MBL screening method be based not only on bacterial species but also on the strains collected and the local prevalence of MBL producers (11, 15).
In conclusion, in our study, the best method for screening for MBL production in P. aeruginosa strains from China was the CD assay (IMP-EDTA) using 750 µg of EDTA/disk with a breakpoint of
6 mm. This method also provides a simple, inexpensive, and reproducible functional screen for MBL-producing P. aeruginosa strains in China.

ACKNOWLEDGMENTS
This work was supported by a research grant from the National
Basic Research Program (the 973 Program) of China (no. 2005CB523101)
and by a research grant from the National Natural Science Foundation
of China (no. NSFC30670930).

FOOTNOTES
* Corresponding author. Mailing address: State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Phone and fax: 86 571 8723 6756. E-mail:
yvys119{at}163.com 
Published ahead of print on 11 February 2009. 

REFERENCES
1 - Andrade, S. S., R. C. Picao, E. H. Campana, A. G. Nicoletti, A. C. Pignatari, and A. C. Gales. 2007. Influence of disk preparation on detection of metallo-β-lactamase-producing isolates by the combined disk assay. J. Clin. Microbiol. 45:2058-2060.[Abstract/Free Full Text]
2 - Berges, L., H. Rodriguez-Villalobos, A. Deplano, and M. J. Struelens. 2007. Prospective evaluation of imipenem/EDTA combined disc and Etest for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa. J. Antimicrob. Chemother. 59:812-813.[Free Full Text]
3 - Castanheira, M., M. A. Toleman, R. N. Jones, F. J. Schmidt, and T. R. Walsh. 2004. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother. 48:4654-4661.[Abstract/Free Full Text]
4 - Conejo, M. C., I. Garcia, L. Martinez-Martinez, L. Picabea, and A. Pascual. 2003. Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47:2313-2315.[Abstract/Free Full Text]
5 - Dumas, J. L., C. van Delden, K. Perron, and T. Kohler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.[CrossRef][Medline]
6 - Franklin, C., L. Liolios, and A. Y. Peleg. 2006. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J. Clin. Microbiol. 44:3139-3144.[Abstract/Free Full Text]
7 - Galani, I., P. D. Rekatsina, D. Hatzaki, D. Plachouras, M. Souli, and H. Giamarellou. 2008. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J. Antimicrob. Chemother. 61:548-553.[Abstract/Free Full Text]
8 - Giakkoupi, P., G. Petrikkos, L. S. Tzouvelekis, S. Tsonas, N. J. Legakis, and A. C. Vatopoulos. 2003. Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals. J. Clin. Microbiol. 41:822-825.[Abstract/Free Full Text]
9 - Gupta, V. 2008. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin. Investig. Drugs 17:131-143.[CrossRef][Medline]
10 - Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.[Abstract/Free Full Text]
11 - Lee, K., D. Yong, J. H. Yum, Y. S. Lim, A. Bolmstrom, A. Qwarnstrom, A. Karlsson, and Y. Chong. 2005. Evaluation of Etest MBL for detection of blaIMP-1 and blaVIM-2 allele-positive clinical isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 43:942-944.[Abstract/Free Full Text]
12 - Lincopan, N., J. A. McCulloch, C. Reinert, V. C. Cassettari, A. C. Gales, and E. M. Mamizuka. 2005. First isolation of metallo-β-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil. J. Clin. Microbiol. 43:516-519.[Abstract/Free Full Text]
13 - Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.[CrossRef][Medline]
14 - Marchiaro, P., M. A. Mussi, V. Ballerini, F. Pasteran, A. M. Viale, A. J. Vila, and A. S. Limansky. 2005. Sensitive EDTA-based microbiological assays for detection of metallo-β-lactamases in nonfermentative gram-negative bacteria. J. Clin. Microbiol. 43:5648-5652.[Abstract/Free Full Text]
15 - Picão, R. C., S. S. Andrade, A. G. Nicoletti, E. H. Campana, G. C. Moraes, R. E. Mendes, and A. C. Gales. 2008. Metallo-β-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J. Clin. Microbiol. 46:2028-2037.[Abstract/Free Full Text]
16 - Pitout, J. D., D. B. Gregson, L. Poirel, J. A. McClure, P. Le, and D. L. Church. 2005. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J. Clin. Microbiol. 43:3129-3135.[Abstract/Free Full Text]
17 - Poirel, L., T. Lambert, S. Turkoglu, E. Ronco, J. Gaillard, and P. Nordmann. 2001. Characterization of class 1 integrons from Pseudomonas aeruginosa that contain the blaVIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob. Agents Chemother. 45:546-552.[Abstract/Free Full Text]
18 - Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891-897.[Abstract/Free Full Text]
19 - Senda, K., Y. Arakawa, S. Ichiyama, K. Nakashima, H. Ito, S. Ohsuka, K. Shimokata, N. Kato, and M. Ohta. 1996. PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J. Clin. Microbiol. 34:2909-2913.[Abstract]
20 - Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
21 - Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, and A. Gales. 2002. Evaluation of a new Etest for detecting metallo-β-lactamases in routine clinical testing. J. Clin. Microbiol. 40:2755-2759.[Abstract/Free Full Text]
22 - Xiong, J., M. F. Hynes, H. Ye, H. Chen, Y. Yang, F. M'Zali, and P. M. Hawkey. 2006. blaIMP-9 and its association with large plasmids carried by Pseudomonas aeruginosa isolates from the People's Republic of China. Antimicrob. Agents Chemother. 50:355-358.[Abstract/Free Full Text]
23 - Yan, J. J., P. R. Hsueh, W. C. Ko, K. T. Luh, S. H. Tsai, H. M. Wu, and J. J. Wu. 2001. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob. Agents Chemother. 45:2224-2228.[Abstract/Free Full Text]
24 - Yatsuyanagi, J., S. Saito, S. Harata, N. Suzuki, Y. Ito, K. Amano, and K. Enomoto. 2004. Class 1 integron containing metallo-β-lactamase gene blaVIM-2 in Pseudomonas aeruginosa clinical strains isolated in Japan. Antimicrob. Agents Chemother. 48:626-628.[Abstract/Free Full Text]
25 - Yong, D., K. Lee, J. H. Yum, H. B. Shin, G. M. Rossolini, and Y. Chong. 2002. Imipenem-EDTA disk method for differentiation of metallo-β-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 40:3798-3801.[Abstract/Free Full Text]
26 - Yu, Y. S., T. T. Qu, J. Y. Zhou, J. Wang, H. Y. Li, and T. R. Walsh. 2006. Integrons containing the VIM-2 metallo-β-lactamase gene among imipenem-resistant Pseudomonas aeruginosa strains from different Chinese hospitals. J. Clin. Microbiol. 44:4242-4245.[Abstract/Free Full Text]
27 - Zavascki, A. P., A. L. Barth, A. L. Goncalves, A. L. Moro, J. F. Fernandes, A. F. Martins, F. Ramos, and L. Z. Goldani. 2006. The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J. Antimicrob. Chemother. 58:387-392.[Abstract/Free Full Text]
Journal of Clinical Microbiology, April 2009, p. 1136-1142, Vol. 47, No. 4
0095-1137/09/$08.00+0 doi:10.1128/JCM.01592-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.